Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection, Published online: 13 February 2018; doi:10.1038/bjc.2017.473

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

http://ift.tt/2G9owIE